← Back to Search

Mobile Health Exercise for Cancer (GO-EXCAP2 Trial)

N/A
Recruiting
Led By Kah Poh Loh
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
Age ≥60 years (conventional definition of older age in clinical trials of MN)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks

Summary

This trial is testing a new mobile health intervention to see if it's more effective than chemotherapy education in improving physical function and patient-reported outcomes in 100 older patients with MN.

Who is the study for?
This trial is for English-speaking older adults (60+) with Myeloid Neoplasms who are undergoing outpatient chemotherapy. They should be able to walk and have an ECOG status of 0-3, indicating varying levels of functional capacity. Those with conditions that prevent exercise or impair participation in the study cannot join.
What is being tested?
The trial is testing a mobile health exercise app called GO-EXCAP against a control group receiving chemotherapy education. The goal is to see if the app improves physical function, mood, fatigue, and quality of life in patients compared to just getting educational support.
What are the potential side effects?
Since this intervention involves exercise facilitated by an app rather than medication, side effects may include typical risks associated with physical activity such as muscle soreness or strain especially given the older population involved.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can care for myself but may not be able to do heavy physical work.
Select...
I am 60 years old or older.
Select...
I have been diagnosed with membranous nephropathy (MN).
Select...
I can walk 4 meters, with or without help from a device.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Difference between experimental and active comparator arms- Physical Function
Secondary study objectives
Difference between experimental and active comparator arms -Depression
Difference between experimental and active comparator arms -Fatigue
Difference between experimental and active comparator arms -Quality of Life
Other study objectives
Difference between experimental and active comparator arms -Inflammatory cytokines
Difference between experimental and active comparator arms- DNA methylation in the TNFα promoter region
Difference between experimental and active comparator arms- TNFα gene expression

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: GO-EXCAPExperimental Treatment1 Intervention
GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program \[Exercise for Cancer Patients (EXCAP©®)\]. EXCAP©®) is a progressive walking and resistance exercise program
Group II: Behavioral Placebo ControlActive Control1 Intervention
Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GO-EXCAP Mobile App
2020
N/A
~30

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor
868 Previous Clinical Trials
549,022 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,927 Previous Clinical Trials
41,017,905 Total Patients Enrolled
7 Trials studying Myeloid Neoplasm
2,565 Patients Enrolled for Myeloid Neoplasm
Kah Poh LohPrincipal InvestigatorUniversity of Rochester
5 Previous Clinical Trials
210 Total Patients Enrolled

Media Library

GO-EXCAP Mobile App Clinical Trial Eligibility Overview. Trial Name: NCT04981821 — N/A
Myeloid Neoplasm Research Study Groups: Behavioral Placebo Control, GO-EXCAP
Myeloid Neoplasm Clinical Trial 2023: GO-EXCAP Mobile App Highlights & Side Effects. Trial Name: NCT04981821 — N/A
GO-EXCAP Mobile App 2023 Treatment Timeline for Medical Study. Trial Name: NCT04981821 — N/A
~17 spots leftby Jun 2025